Optum Rx Upends PBM Model with Full Transparency Fee Structure

EDEN PRAIRIE, MN – May 11, 2026 – Optum Rx, one of the nation’s largest pharmacy benefit managers, today announced a sweeping overhaul of its business model, a move that signals a seismic shift in the historically opaque prescription drug industry. The company is transitioning all of its clients to a new transparent, fee-based pricing structure, effectively dismantling the controversial practices that have drawn intense scrutiny from lawmakers, regulators, and the public.

Under the new system, Optum Rx will replace its traditional pricing—often tied to the list price of drugs or the volume of prescriptions—with a simplified model based on a fixed per-member, per-month fee. The company has committed to eliminating “spread pricing,” a practice where a PBM charges a health plan more for a medication than it reimburses the pharmacy, pocketing the difference. This new approach promises to provide employers and health plans with unprecedented clarity and predictability in their pharmacy spending.

“This new Optum Rx model builds on our longstanding commitment to lowering costs and strengthening transparency by offering our clients a simpler and more predictable pharmacy system,” said Dr. Patrick Conway, CEO of Optum, in a statement accompanying the announcement.

A Response to an Industry Under Fire

Optum Rx’s pivot comes as the entire Pharmacy Benefit Manager (PBM) industry weathers a storm of criticism and regulatory pressure. PBMs, which act as powerful intermediaries between drug manufacturers, health plans, and pharmacies, have been accused of contributing to rising healthcare costs through complex and secretive business practices. For years, critics have argued that the PBM model, which processes nearly 80% of all U.S. prescription claims through its top three players, creates misaligned incentives.

The traditional model often rewards PBMs for steering patients toward higher-priced drugs that come with larger manufacturer rebates, a portion of which the PBMs retain. This system has been blamed for inflating drug costs and obscuring the true price of medications. The lack of transparency has made it nearly impossible for clients—the employers and health plans paying the bills—to understand what they are paying for and how much of their spending is profit for the middleman.

This frustration has culminated in significant government action. The Federal Trade Commission (FTC) has been conducting an extensive inquiry into the PBM industry since 2022, with interim reports criticizing the effects of market consolidation and opaque practices on independent pharmacies and consumers. Simultaneously, state legislatures across the country have passed a flurry of laws aimed at forcing transparency, banning spread pricing, and regulating PBM conduct.

Deconstructing the “Industry First” Claim

While Optum Rx is branding its new system as an “industry’s first transparent pharmacy care model,” it is entering a race to reform that its chief rivals have already joined. In response to the same market and regulatory pressures, both Express Scripts and CVS Caremark have launched their own transparency initiatives over the past few years.

In 2023, Express Scripts rolled out its ClearCareRx model, promising clients 100% pass-through of rebates and a simple administrative fee. It followed up with ClearNetwork, a cost-plus pricing model for its pharmacy network. Similarly, CVS Caremark announced its TrueCost and CostVantage models, designed to move reimbursement toward a model based on the acquisition cost of drugs plus a defined markup and fee.

Where Optum Rx’s announcement may break new ground is in its scope and mandatory application. The company has stated the new fee-based structure will be offered to every Optum Rx PBM customer, representing a complete, system-wide transition away from older pricing models rather than offering transparency as an optional product. This comprehensive overhaul, set to be fully implemented by the end of 2027, suggests a strategic decision to get ahead of a market that is irrevocably shifting toward transparency.

The Ripple Effect on Employers, Patients, and Pharmacies

The move is designed to have a direct impact on every stakeholder in the prescription drug chain. For plan sponsors like employers and health unions, the shift to a predictable, flat-fee structure is a welcome change. It promises to simplify budgeting and provide clear sightlines into where their healthcare dollars are going. The commitment to pass through 100% of manufacturer rebates to clients by 2028, a move now being mandated by federal law, further aligns the PBM’s role with the client’s goal of lowering costs.

Patients are also promised more direct benefits through new digital tools. ‘Shop MyScript’ will alert patients to medication costs and pharmacy options immediately after a prescription is written, allowing them to make choices before arriving at the pharmacy counter. A second tool, ‘Price Wise,’ will display a full cost breakdown for those paying without insurance, demystifying the final price.

Independent pharmacies, which have long been vocal critics of PBM reimbursement practices, may also see some relief. The announcement builds on steps Optum Rx took in 2025 to transition its network of community pharmacies to cost-based payment terms, designed to better reflect the actual costs pharmacies incur. This, combined with the earlier elimination of retroactive “clawback” fees, is intended to create a more stable and predictable financial environment for these essential local providers.

Navigating a New Regulatory Gauntlet

Optum Rx’s strategic overhaul is not happening in a vacuum. It is a direct and calculated response to a rapidly changing legal landscape. The federal Consolidated Appropriations Act, passed in February 2026, contains sweeping PBM reforms that mirror many of the changes Optum is now implementing. The law mandates 100% rebate pass-through to employer health plans and prohibits PBM compensation in Medicare from being tied to a drug's list price, effectively outlawing some of the industry’s most profitable arrangements.

At the state level, a patchwork of aggressive legislation has already put PBMs on the defensive. States like Colorado and California have passed “delinking” laws that force a move to flat-fee models, while others have focused on strict reporting requirements and banning PBMs from steering patients away from local pharmacies. By voluntarily adopting a model that aligns with these new federal and state regulations, Optum Rx positions itself as a proactive reformer rather than a reluctant target of government enforcement.

This shift toward transparent, fee-for-service models fundamentally alters the PBM value proposition, moving it away from navigating a complex web of hidden rebates and toward a more straightforward administrative and clinical service. While this new structure promises to cure some of the industry’s most criticized ailments, the ultimate trajectory of prescription drug costs still largely depends on the list prices set by pharmaceutical manufacturers. The new transparency may reveal where the money goes, but the fight over how much things cost in the first place is far from over.